Skip to main content

Table 5 Cox regression survival analyses

From: Clinical value of selected markers of angiogenesis, inflammation, insulin resistance and obesity in type 1 endometrial cancer

 

Hazard ratio

95% CI for HR

Total P-value

Univariate analysis

 Base model

 FIGO stage

 III-IV vs I-II

5.98

3.11–9.89

< 0.001

 Age (years)

 > 60 vs ≤60

2.31

1.24–4.58

0.013

 Grade

 1 vs 2

2.59

1.16–4.86

0.062

 Myometrial invasion

 > 50% vs ≤50%

3.28

1.83–5.92

< 0.001

 LVSI

 yes vs no

2.63

1.24–4.76

0.009

 Additions to modela

 VEGF-A

1.02

0.25–3.64

0.74

 Ang-2

1.29

1.09–1.59

< 0.001

 Adiponectin

1.01

0.99–1.06

0.923

 Insulin

1.00

0.98–1.02

0.914

 C-peptide

1.02

0.97–1.06

0.689

 CRP

1.37

1.03–1.61

< 0.001

 IGF-1

1.01

0.96–1.05

0.893

 BMI

0.84

0.45–1.41

0.472

Multivariate analysis

 Base model

 FIGO stage

 III-IV vs I-II

3.57

1.79–6.94

< 0.001

 Age (years)

 > 60 vs ≤60

2.21

1.19–4.32

0.017

 Grade

 1 vs 2

1.52

1.18–2.96

0.683

 Myometrial invasion

 > 50% vs ≤50%

1.11

0.49–2.09

0.861

 LVSI

 yes vs no

1.16

0.53–2.36

0.734

Additions to modelb

 Ang-2

1.31

1.02–1.69

0.006

 CRP

1.22

1.01–1.43

0.015

  1. aThe base model consisted of traditional prognostic factors, and we separately entered the parameters in a second block
  2. bAdditions to the used model (all continuous, log-transformed, and separately entered)